SCHEMBL6152882

SCHEMBL6152882

COC(=O)C1=C(CCc2ccccc2COCCN2CCOCC2)NC(CC(=O)O)=C(C(=O)OC)C1c1c(Cl)cccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
APOBEC3A P31941 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ESR2 Q92731 1/20 0.36
PTAFR P25105 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTR1A P08908 2/20 0.35
ADRA2A P08913 2/20 0.35
CHRM1 P11229 2/20 0.35
DRD1 P21728 2/20 0.35
TBXA2R P21731 2/20 0.35
SLC6A2 P23975 2/20 0.35
ADRA1A P35348 2/20 0.35
OPRM1 P35372 2/20 0.35
DRD3 P35462 2/20 0.35
SLC6A3 Q01959 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153190 0.94 SMN1; SMN2 (0.37) POLBSMN1; SMN2APOBEC3AAPOBEC3GMEN1
SCHEMBL6152414 0.93 PTAFR (0.37) MEN1KMT2AHRH3PTAFRL3MBTL1
SCHEMBL7245208 0.89 POLB (0.39) POLBSMN1; SMN2MEN1KMT2AHRH3
SCHEMBL6152973 0.85 PTAFR (0.32) POLBSMN1; SMN2APOBEC3AAPOBEC3GMEN1
SCHEMBL6153062 0.82 HPGD (0.34) MEN1KMT2AHRH3L3MBTL1ALDH1A1
SCHEMBL6152944 0.80 ADRA1A (0.36) SMN1; SMN2MEN1KMT2AHTR1AADRA2A
SCHEMBL7691800 0.80 POLB (0.37) POLBSMN1; SMN2APOBEC3AAPOBEC3GMEN1
SCHEMBL6152510 0.79 POLB (0.33) POLBSMN1; SMN2HRH3L3MBTL1KDM4E
SCHEMBL7245220 0.79 TBXA2R (0.47) SMN1; SMN2MEN1KMT2APTAFRHTR1A
SCHEMBL6155788 0.78 PTAFR (0.33) PTAFRHTR1AADRA2ACHRM1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307449-B1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMA (JP) 2005-12-07 EP disclosed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 POLB 4177/4885SMN1; SMN2 4324/4885APOBEC3A 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.